{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:56:22Z","timestamp":1755795382382,"version":"3.44.0"},"reference-count":33,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2021,9,23]]},"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess current management practice of heart failure with reduced ejection fraction (HFrEF) in multinational primary care (PC) and determine whether N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP)-guided referral of HFrEF patients from PC to a cardiologist could improve care, defined as adherence to European Society of Cardiology (ESC) guideline-recommended pharmacotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic HF in PC (PREFER) study enrolled HFrEF patients from PC considered clinically stable and those with NT-pro-BNP \u2265600\u2009pg\/mL were referred to a cardiologist for optimisation of HF treatment. The primary outcome of adherence to ESC HF guidelines after referral to specialist was assessed at the second visit within 4 weeks of cardiologist\u2019s referral and no later than 6 months after the baseline visit. Based on futility interim analysis, the study was terminated early.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 1415 HFrEF patients from 223 PCs from 18 countries in Europe were enrolled. Of these, 1324 (96.9%) were considered clinically stable and 920 (65.0%) had NT-pro-BNP \u2265600\u2009pg\/mL (mean: 2631\u2009pg\/mL). In total, 861 (60.8%) patients fulfilled both criteria and were referred to a cardiologist. Before cardiologist consultation, 10.1% of patients were on ESC guideline-recommended HFrEF medications and 2.7% were on recommended dosages of HFrEF medication (defined as \u226550% of ESC guideline-recommended dose). Postreferral, prescribed HFrEF drugs remained largely unchanged except for an increase in diuretics (+4.6%) and mineralocorticoid receptor antagonists (+7.9%). No significant increase in patients\u2019 adherence to guideline-defined drug combinations (11.2% post-referral vs 10.1% baseline) or drug combinations and dosages (3.3% postreferral vs 2.7% baseline) was observed after cardiologist consultation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PREFER demonstrates substantial suboptimal treatment of HFrEF patients in the real world. Referral of patients with elevated NT-pro-BNP levels from PC to cardiologist did not result in meaningful treatment optimisation for treatments with known mortality and morbidity benefit.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2021-001630","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T14:12:29Z","timestamp":1634739149000},"page":"e001630","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER): a real-world study"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02807857","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7976-7172","authenticated-orcid":false,"given":"FD Richard","family":"Hobbs","sequence":"first","affiliation":[{"name":"University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan I","family":"Hussain","sequence":"additional","affiliation":[{"name":"Arxx Therapeutics, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Vitale","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, IRCCS San Raffaele Pisana, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yigal M","family":"Pinto","sequence":"additional","affiliation":[{"name":"Departments of Cardiology and Experimental Cardiology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector","family":"Bueno","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Lequeux","sequence":"additional","affiliation":[{"name":"Poitiers University Hospital, Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Pauschinger","sequence":"additional","affiliation":[{"name":"Department of Cardiology, General Hospital Nuremberg, Nuremburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Obermeier","sequence":"additional","affiliation":[{"name":"GKM Gesellschaft f\u00fcr Therapieforschung mbH, Munchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe C","family":"Ferber","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"2025081711135018000_8.2.e001630.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-018-0815-3","article-title":"Cost-Of-Illness studies in heart failure: a systematic review 2004-2016","volume":"18","author":"Lesyuk","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"2025081711135018000_8.2.e001630.2","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-016-0211-2"},{"key":"2025081711135018000_8.2.e001630.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11601-1"},{"key":"2025081711135018000_8.2.e001630.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfn006"},{"key":"2025081711135018000_8.2.e001630.5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s12471-020-01487-x","article-title":"Training general practitioners to improve evidence-based drug treatment of patients with heart failure: a cluster randomised controlled trial","volume":"28","author":"Valk","year":"2020","journal-title":"Neth Heart J"},{"key":"2025081711135018000_8.2.e001630.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.06.023"},{"key":"2025081711135018000_8.2.e001630.7","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ejhf.1459","article-title":"Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the qualify international registry","volume":"21","author":"Komajda","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2025081711135018000_8.2.e001630.8","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.80.5.437"},{"key":"2025081711135018000_8.2.e001630.9","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hft050"},{"key":"2025081711135018000_8.2.e001630.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.070"},{"key":"2025081711135018000_8.2.e001630.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.10.010"},{"key":"2025081711135018000_8.2.e001630.12","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hft134"},{"key":"2025081711135018000_8.2.e001630.13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"2025081711135018000_8.2.e001630.14","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.705"},{"key":"2025081711135018000_8.2.e001630.15","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-014-9439-6"},{"key":"2025081711135018000_8.2.e001630.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(19)32971-7"},{"key":"2025081711135018000_8.2.e001630.17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/02813432.2017.1397253","article-title":"Adherence to guidelines in patients with chronic heart failure in primary health care","volume":"35","author":"Giezeman","year":"2017","journal-title":"Scand J Prim Health Care"},{"key":"2025081711135018000_8.2.e001630.18","doi-asserted-by":"crossref","unstructured":"DeVore AD , Mi X , Thomas L , et al . Characteristics and treatments of patients enrolled in the CHAMP\u2010HF registry compared with patients enrolled in the PARADIGM\u2010HF trial. J Am Heart Assoc 2018;7.doi:10.1161\/JAHA.118.009237","DOI":"10.1161\/JAHA.118.009237"},{"key":"2025081711135018000_8.2.e001630.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013459"},{"key":"2025081711135018000_8.2.e001630.20","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/ejhf.1248","article-title":"The misperception of 'stable' heart failure","volume":"20","author":"Pascual-Figal","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2025081711135018000_8.2.e001630.21","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2009.197"},{"key":"2025081711135018000_8.2.e001630.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7492.625"},{"key":"2025081711135018000_8.2.e001630.23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.929661"},{"key":"2025081711135018000_8.2.e001630.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2013.04.007"},{"key":"2025081711135018000_8.2.e001630.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.7588"},{"key":"2025081711135018000_8.2.e001630.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.069"},{"key":"2025081711135018000_8.2.e001630.27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.10565"},{"key":"2025081711135018000_8.2.e001630.28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.15420\/cfr.2018.26.1","article-title":"Natriuretic peptides in chronic heart failure","volume":"5","author":"Brunner-La Rocca","year":"2019","journal-title":"Card Fail Rev"},{"key":"2025081711135018000_8.2.e001630.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.04.069"},{"key":"2025081711135018000_8.2.e001630.30","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.115"},{"key":"2025081711135018000_8.2.e001630.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021856"},{"key":"2025081711135018000_8.2.e001630.32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40256-018-0277-0","article-title":"Stable but progressive nature of heart failure: considerations for primary care physicians","volume":"18","author":"Anand","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025081711135018000_8.2.e001630.33","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002735","article-title":"Factors associated with Noncompletion during the Run-In period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF trial","volume":"9","author":"Desai","year":"2016","journal-title":"Circ Heart Fail"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2021-001630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T18:14:00Z","timestamp":1755454440000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2021-001630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,10,20]]},"published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1136\/openhrt-2021-001630"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2021-001630","relation":{},"ISSN":["2053-3624"],"issn-type":[{"type":"electronic","value":"2053-3624"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}